In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Diabetes Care

Division of Panasonic Healthcare Holdings Co. Ltd.
www.diabetes.bayer.com

Latest From Bayer Diabetes Care

Market Intel: Needle-Free Glucose Monitoring, Digital Solutions Are Game-Changers In Growing Diabetes-Monitoring Market

The global blood glucose monitoring devices market is expected to exceed $7bn by 2022, driven by the smaller, but fastest-growing continuous glucose monitoring (CGM) segment, which is expanding at double-digits. The much bigger blood glucose meter (BGM) segment, meanwhile, is facing increased competition from lower-cost manufacturers, innovative startups and tech giants like Apple that are attracting consumers with smart devices and packaged diabetes management solutions. This first of a two-part series looks more closely at the competitive landscape of the two major product segments – BGM and CGM – with insights from endocrinologists. The second part will focus on the pros and cons of using diabetes management apps and highlights the best diabetes apps.

Diabetic Care Digital Health

Market Intel: Advent Of Artificial Pancreas Tech To Galvanize Fast-Growing Diabetes Market

The global diabetes management devices market is expected to exceed $11.2bn by 2020, driven largely by the rising diabetes epidemic. This, in turn, is fueling significant innovation such as next-generation, automated artificial pancreas systems and miniaturized, less-invasive wireless technologies that can continuously track and analyze glucose levels in real-time. This feature looks more closely at these and other potentially groundbreaking new technologies, as well as the competitive landscape of the two major product segments – insulin pumps and blood glucose monitors.

Diabetic Care Metabolic

Device/Diagnostics Quarterly Deal Statistics, Q2 2015

At $1.8 billion, Q2 device financing nearly doubled the Q1 total, mainly from an increase in IPOs and early VC rounds, and acquisitions were slightly higher at $4.7 billion. Diagnostics funding also increased to $784 million from Q1's $597 million, and Danaher's monster $13.8 billion buy of life sciences company Pall headlined the second quarter's $15.6 billion total in diagnostics M&A activity.

Medical Device Deals

Deals In Depth: June/July 2015

Sanofi and Regeneron teamed up in a second major deal, focused on immuno-oncology; after an unsuccessful try at Mylan, Teva bought Allergan's generics business. Between June and July, biopharma companies raised over $10 billion, and device firms more than $1 billion.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Glucose Testing
  • Medical Devices
    • Monitoring Equipment & Devices
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Panasonic Healthcare Holdings Co. Ltd.
  • Senior Management
  • Alan Main, Pres. Bayer Medical Care
    Michael Kloss, Global Head, Commercial Ops.
    Christiane Pering, MD, CMO & Head, Innovation
  • Contact Info
  • Bayer Diabetes Care
    Phone: (800) 348-8100
    100 Bayer Blvd.
    P.O. Box 915 Whippany, NJ 07981-0915
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register